Physician profile
Erwin E Feldman
NPI 1053426049
$889.85
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $205 · 2021: $341 · 2022: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $135.56 | 2019-2020 | |
| Glaxosmithkline, LLC. | $129.68 | 2019-2022 | |
| Lilly USA, LLC | $125.81 | 2020-2022 | |
| Pfizer INC. | $115.91 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.80 | 2019-2021 | |
| Novo Nordisk INC | $73.61 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.26 | 2021-2022 | |
| Allergan, INC. | $41.95 | 2020 | |
| Novartis Pharmaceuticals Corporation | $30.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.30 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.26 | 2021 | |
| Abbvie INC. | $15.64 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $15.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.12 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erwin Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.